Versantvoort C H, Broxterman H J, Bagrij T, Scheper R J, Twentyman P R
Medical Research Council, Clinical Oncology and Radiotherapeutics Unit, Cambridge, UK.
Br J Cancer. 1995 Jul;72(1):82-9. doi: 10.1038/bjc.1995.281.
Previous studies have shown that multidrug resistance (MDR) in the doxorubicin-selected lung tumour cell lines COR-L23/R, GLC4/ADR and MOR/R is associated with overexpression of the MRP gene. In this study we report that resistance to daunorubicin, vincristine and rhodamine 123 can be partially reversed in these cell lines by exposing the cells to buthionine sulphoximine (BSO), an inhibitor of glutathione (GSH) synthesis. This effect of BSO on drug resistance was associated with an increased intracellular accumulation of daunorubicin and rhodamine 123, owing to inhibition of the enhanced drug efflux. In contrast, the accumulation of daunorubicin was not increased by BSO treatment in a P-glycoprotein (P-gp)-mediated MDR cell line. BSO treatment (25 microM, 20 h) of the cell lines resulted in 60-80% depletion of cellular GSH levels. The effects of BSO on daunorubicin accumulation in the COR-L23/R and GLC4/ADR cells were associated with cellular GSH depletion. In addition, increase of cellular GSH levels in BSO-treated COR-L23/R and GLC4/ADR cells as a result of incubation with 5 mM GSH ethyl ester restored the accumulation deficit of daunorubicin. However, the transport of daunorubicin did not increase the GSH release in any of the cell lines. These results demonstrate that drug transport in MRP- but not in P-gp-overexpressing MDR tumour cell lines can be regulated by intracellular GSH levels.
先前的研究表明,在阿霉素筛选的肺癌细胞系COR-L23/R、GLC4/ADR和MOR/R中,多药耐药性(MDR)与MRP基因的过表达有关。在本研究中,我们报告,通过将细胞暴露于谷胱甘肽(GSH)合成抑制剂丁硫氨酸亚砜胺(BSO),这些细胞系对柔红霉素、长春新碱和罗丹明123的耐药性可部分逆转。BSO对耐药性的这种作用与柔红霉素和罗丹明123细胞内蓄积增加有关,这是由于增强的药物外排受到抑制。相比之下,在P-糖蛋白(P-gp)介导的MDR细胞系中,BSO处理并未增加柔红霉素的蓄积。用BSO(25 microM,20小时)处理细胞系导致细胞GSH水平耗竭60-80%。BSO对COR-L23/R和GLC4/ADR细胞中柔红霉素蓄积的影响与细胞GSH耗竭有关。此外,用5 mM GSH乙酯孵育后,BSO处理的COR-L23/R和GLC4/ADR细胞中细胞GSH水平的增加恢复了柔红霉素的蓄积缺陷。然而,柔红霉素的转运在任何细胞系中均未增加GSH释放。这些结果表明,可以通过细胞内GSH水平调节MRP过表达而非P-gp过表达的MDR肿瘤细胞系中的药物转运。